Kathiawad Today

Huntington’s Disease Market

DelveInsight’s “Huntington’s Disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Huntington’s Disease, historical and forecasted epidemiology as well as the Huntington’s Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Huntington’s Disease market report provides current treatment practices, emerging drugs, Huntington’s Disease market share of the individual therapies, current and forecasted Huntington’s Disease market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Huntington’s Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Huntington’s Disease market.

Some of the Key Facts of the Huntington’s Disease  Market Report:

• According to DelveInsight’s analysis, the age-specific diagnosed prevalent cases of Huntington’s disease for the age groups
• In the 7MM, the total drug-treated cases of Huntington’s disease were observed as ~38,000 cases in 2020, which is expected to rise in the coming years.

Key Benefits of the Huntington’s Disease Market report

• The report covers the descriptive overview of Huntington’s Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Huntington’s Disease epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Huntington’s Disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Huntington’s Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Huntington’s Disease market

Got queries? Click here to know more about the Huntington’s Disease Market Landscape

Huntington’s Disease Overview

Huntington’s disease, also called Huntington chorea, a relatively rare, and invariably fatal, hereditary neurological disease that is characterized by irregular and involuntary movements of the muscles and progressive loss of cognitive ability. It is inherited as an autosomal dominant trait. In dominant disorders, a single copy of the disease gene (received from either the mother or father) will be expressed “dominating” the other normal gene, resulting in the expression of the disease. The disease is caused by variations (mutations) of a gene (huntingtin) that is located on the short arm (p) of chromosome 4 (4p16.3). Huntington’s disease is clinically characterized by a triad of motor, cognitive, and psychiatric symptoms. Motor features include impairment of involuntary (chorea) and voluntary movements, reduced manual dexterity, slurred speech, swallowing difficulties, balance problems, and falls.The diagnosis of Huntington’s disease is based on a general physical exam, a review of the patient’s family medical history, as well as neurological, psychiatric examinations, and genetic testing.

The current treatment regimen of HD is entirely dependent on symptomatic therapies and includes a cocktail of antidepressants, antipsychotics, and antiepileptics to control patients’ cognitive, behavioral, and neurological symptoms. The goal of the treatment regimen is to slow down the disease progression, survival rate and improve quality of life. The two US FDA approved therapies for chorea associated Huntington’s disease are Deutetrabenazine and tetrabenazine. The dynamics of the Huntington’s disease therapeutic market is anticipated to change in the coming years owing to the improvement in the research and development undertaking. Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication, in order to provide a cure for the disease as well as better relief for the symptoms and hence improve the Quality of life (QoL) of patients with Huntington’s disease.

Huntington’s Disease Epidemiological Insights

• Huntington’s disease is also known as a family disease because every child of a parent with the disease has a 50/50 chance of inheriting the faulty gene. If a parent has the Huntington’s disease gene, there is a one in two (50%) chance of each of their children developing the condition – affected children are also able to pass the gene to any children they have and One in two (50%) chance of each of their children never developing the condition – unaffected children cannot pass the condition on to any children they have.
• The total prevalent population of Huntington’s disease in the 7MM in 2020 were approximately 80,000. These cases are expected to rise by 2032, during the forecast period [2019–2032]. 
• According to DelveInsight’s analysis, in the 7MM, United States reported the highest prevalent cases of Huntington’s disease, i.e., ~42k  which accounted for over 50% of the total 7MM cases, in the year 2020.
• Among the EU-5 countries, Germany reported the highest number of diagnosed prevalent cases of Huntington’s disease, i.e., approximately 4,500  cases in the year 2020. 

 Huntington’s Disease Epidemiological Segmentation 

• Total Huntington’s Disease prevelant cases
• Total Huntington’s Disease diagnosed cases by age group
• Total Huntington’s Disease diagnosed cases by clinical stage
• Total Huntington’s Disease treated cases

Huntington’s Disease  Market Outlook 

The Huntington’s Disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Huntington’s Disease market trends by analyzing the impact of current Huntington’s Disease therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Huntington’s Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Huntington’s Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Huntington’s Disease market in 7MM is expected to witness a major change in the study period 2019-2032.

Learn more by requesting for sample @ Huntington’s Disease Market Landscape

Huntington’s Disease Key Companies

• Neurocrine Biosciences
• Pridopidine
• Annexon
• And many more

Huntington’s Disease  Therapies 

• Valbenazine (Ingrezza)
• Pridopidine
• ANX005
• And many more

 Table of Contents

•   Key Insights 
•   Report Introduction 
•   Executive Summary of Huntington’s Disease  
•   Disease Background and Overview
•   Epidemiology and patient population
•   The United States 
•   EU 5
•   Huntington’s Disease   Emerging Therapies
•   Huntington’s Disease  Market Outlook
•  Market Access and Reimbursement of Therapies
•  Appendix
•  Huntington’s Disease   Report Methodology
•  DelveInsight Capabilities
•  Disclaimer
•  About DelveInsight

Click here to read more about Huntington’s Disease  Market Landscape

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com